Journal of Child and Adolescent Psychopharmacology · 2007 · 76 citations · 13 references
MedicinePharmacokineticsPharmacologyClinical PharmacologyNeuropharmacologyPsychopharmacologyAttention-deficit/hyperactivity DisorderPediatric PharmacokineticsPediatric PharmacologyPediatric PsychopharmacologyPsychopharmacology In ChildrenStimulant TherapyAdhd Medication TitrationAdhd PharmacotherapyAdhd TreatmentMemantine PharmacokineticsNmda Receptor AntagonismNmda Receptor AntagonistsPilot Study DesignSerious Adverse Events
BACKGROUND: Disturbances in N-methyl-D-aspartate (NMDA) receptor activity may play a role in attention-deficit/hyperactivity disorder (ADHD). OBJECTIVE: This study is a preliminary evaluation of the safety, pharmacokinetics, and effectiveness of the NMDA receptor antagonist memantine in pediatric ADHD. METHODS: An open-label, dose-finding, 8-week, trial in outpatients 6-12 years old with ADHD combined type. Memantine oral solution (2 mg/mL) was titrated to 10 mg/day (n = 8) or 20 mg/day (n = 8). Safety data and blood samples for pharmacokinetic analyses were collected. The ADHD Rating Scale-IV (ADHD-IV) and Clinical Global Impression of Severity (CGI-S) scale measured the effectiveness of memantine. RESULTS: There were no discontinuations due to adverse events (AEs), serious AEs, deaths, or suicides. Most AEs were mild and occurred during the first week of treatment. The 20 mg/day memantine dose was associated with a higher rate of completion and larger mean improvement on the ADHD-IV and CGI-S than 10 mg/day memantine. Pharmacokinetic analyses suggest response to memantine may be dose-dependent beyond an initial threshold concentration. CONCLUSIONS: This pilot study suggests that a memantine dose of 20 mg/day may be a safe and possibly effective treatment for pediatric ADHD. Further investigations of memantine in ADHD appear to be warranted.
13
Joan Kaufman, Boris Birmaher, David A. Brent et al. · Journal of the American Academy of Child & Adolescent Psychiatry · 1997 · 10.2K citations · Full text
Memantine in Moderate-to-Severe Alzheimer's Disease
Barry Reisberg, Rachelle S. Doody, Albrecht Stöffler et al. · New England Journal of Medicine · 2003 · 2K citations · Full text
Medicine, Neuroscience, Pharmacology +16
Ronald C. Kessler, Lenard A. Adler, Russell A. Barkley et al. · Biological Psychiatry · 2005 · 663 citations · Full text
Medicine, Psychiatry, Psychology +14
Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia
Jean‐Marc Orgogozo, Anne‐Sophie Rigaud, Albrecht Stöffler et al. · Stroke · 2002 · 538 citations